▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #416 by analyst upside · 2026-08-12
SPRB
Spruce Biosciences, Inc.
Healthcare · Market Cap $128M · P/E 0x
ANALYST PRICE TARGET
+225.4%
implied upside to consensus target
Current Price $46.41
Consensus Target $151.0
Bull Target $230.0
Bear Target $120.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $7.0
52-Week High $240.0
YTD Return -48.8%
FUNDAMENTALS
Market Cap $128M
P/E Ratio (TTM) N/A
Forward P/E 6.3x
EPS (TTM) $-35.82
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.0
52-Week High $240.0
Current Price $46.41
Bear Target $120.0
Bull Target $230.0
● Now $46.41 ● Target $151.0
TRADING DATA
Avg Volume 64K
YTD Return -48.8%
Analyst Count 8
Consensus Buy
Upside to Target +225.4%
Last Updated 2026-08-12

ANALYST SUMMARY

Spruce Biosciences, Inc. (SPRB) is currently trading at $46.41 with a Wall Street consensus price target of $151.0, implying potential upside of 225.4% over the next 12 months. 8 analysts currently cover SPRB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $230.0, while the most cautious has a target of $120.0.

SPRB operates in the Healthcare sector with a market capitalisation of $128M. The stock is down 48.8% year-to-date and is currently trading near the lower end of its 52-week range of $7.0 – $240.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

SPRO +225.2%
Spero Therapeutics, Inc.
$71M · P/E 4.6x · Hold
AGEN +185.5%
Agenus Inc.
$307M · P/E 2.3x · Buy
CCLD +151.0%
CareCloud, Inc.
$104M · P/E 34.9x · Buy
NAGE +292.3%
Niagen Bioscience, Inc.
$244M · P/E 16.2x · Buy
SABS +209.5%
SAB Biotherapeutics, Inc.
$342M · P/E 15.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SPRB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Guggenheim ● Initiated
Buy 2026-06-16 62% win rate (8 calls)
Jones Trading ● Initiated
Buy 2026-06-09 57% win rate (14 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-01 31% win rate (48 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-14 Building track record
Craig-Hallum ● Initiated
Buy 2026-04-27 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-10 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-10 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-02-19 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →